Acrivon Therapeutics, Inc. ( (ACRV) ) has released its Q3 earnings. Here is a breakdown of the information Acrivon Therapeutics, Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Acrivon Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing precision medicines using its proprietary Acrivon Predictive Precision Proteomics (AP3) platform, primarily targeting oncology. The company is advancing its pipeline of small molecule inhibitors, including ACR-368 and ACR-2316, which are in various stages of clinical trials.
In its latest earnings report for the quarter ended September 30, 2025, Acrivon Therapeutics reported a net loss of $18.2 million, compared to a net loss of $22.4 million in the same period last year. The company’s total operating expenses decreased to $19.7 million from $25.1 million in the previous year, driven by reduced research and development costs. Despite the losses, the company maintains a strong cash position with $134.4 million in cash, cash equivalents, and investments.
Key highlights from the report include the ongoing Phase 2 trial of ACR-368, which has shown promising results with a 35% confirmed overall response rate in endometrial cancer patients. Additionally, ACR-2316 is progressing through Phase 1 trials, demonstrating significant drug target engagement and initial clinical activity in solid tumor types.
Looking forward, Acrivon Therapeutics remains focused on advancing its clinical trials and leveraging its AP3 platform to identify and develop new drug candidates. The company anticipates the need for additional funding to support its operations beyond the second quarter of 2027, as it continues to pursue its strategic objectives in the competitive biotechnology sector.